Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections.
Daniel A SweeneyBonifride TuyishimireNeera AhujaJohn H BeigelTatiana BeresnevValeria D CantosJose G CastroStuart H CohenKaitlyn CrossLori E DoddNathan ErdmannMonica FungVarduhi GhazaryanSarah L GeorgeKevin A GrimesNoreen A HynesKathleen G JulianSheetal KandiahHannah Jang KimCorri B LevineDavid A LindholmDavid C LyeRyan C MavesMyoung-Don OhCatharine PaulesRekha R RapakaWillam R ShortKay M TomashekCameron R WolfeAndre C KalilPublished in: Open forum infectious diseases (2023)
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.